NCT06628921

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: University of Florence · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)

Conditions

• Migraine

Interventions

Type	Name	Description
DRUG	Eptinezumab 100 or 300 mg ev	Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.

Timeline

• Start date: 2024-10-30
• Primary completion: 2026-10-30
• Completion: 2026-10-30
• First posted: 2024-10-08
• Last updated: 2026-01-21

Locations

1 site across 1 country: Italy

Regulatory

• FDA-regulated drug study